4Lupus in the developing world – is it any different?
Section snippets
Epidemiology
Over the past 50–60 years there has been a rise of more than ten-fold in the annual incidence of SLE in industrialized Western countries.1 This temporal increase in SLE is thought to be due to both a true increase in incidence, related to exposure to environmental factors, and increased recognition of the disease. The epidemiology of SLE in the developing world remains largely unknown. Where formal epidemiological studies have been undertaken, the occurrence of SLE has been found to be within
Clinical and serological features
Studies from Western industrialized countries consistently show that the severity and burden of SLE is greatest in non-Caucasian ethnic groups of African and Asian extraction.*1, 22, *23 The clinical spectrum (Table 1), autoantibody profile, and comorbidity of SLE in the developing world are not dissimilar to those in non-Caucasian SLE patients living in industrialized countries.
Co-morbidity of infections
Infections are among the most important causes of morbidity and mortality in SLE across all regions.58 Several series in developing countries rank infections as either first or second to SLE disease activity as a cause or contributor to mortality (Table 2).*19, 20, *27, 40, 59, 60, 61, 62 This susceptibility to infection may be explained by several intrinsic and acquired defects in the immune system related to the disease itself or to the immunosuppressive therapies.20, 63, 64 Among the genetic
Variations in therapeutic approach due to resource constraints
The outcomes – including survival – in SLE are largely influenced by factors which include socioeconomic status, educational attainment, access to health care, physician availability, and treatment adherence.12, *77, 78 These interdependent factors are very important in developing countries where poverty remains widespread, and many patients live in rural areas where access to medical care is often rudimentary.12 The economic costs due to loss in productivity, both in household and workforce
Factors contributing to differences in outcome
Two major features characterize the divergence of outcome between the two ‘worlds’. Firstly, with few exceptions, survival rates in developing countries are substantially lower (Table 2) than in the industrialized world where 5-year survival rates for SLE are well in excess of 90%.82, 83 Secondly, the bimodal pattern of mortality that has emerged in industrialized countries in recent years, where active lupus and infections accounting for most early deaths (within 5 years of onset of disease)
Summary
In summary, there is clear evidence that SLE varies in spectrum and severity in the developing world compared to the industrialized world. While these differences are to some extent the result of inter-ethnic genetic differences, many of the differences in morbidity and mortality reflect disparities in health services across the globe.
The outlook for SLE patients in the developing world can be improved only by new initiatives undertaken by both private and government sectors: to better define
References (96)
Low frequency of autoimmune disease in tropical Africa
Lancet
(1997)- et al.
Systemic lupus erythematosus in migrants from west Africa compared with Afro-Caribbean people in the UK
Lancet
(2001) - et al.
European Working Party on Systemic Lupus Erythematosus: a 15-year report
Autoimmunity Reviews
(2006) - et al.
Lupus nephritis in Thailand: clinicopathologic findings and outcome in 569 patients
American Journal of Kidney Diseases: the official journal of the National Kidney Foundation
(1995) - et al.
The clinical and epidemiologic features in 140 patients with lupus nephritis in a predominantly black population from one center in Kingston, Jamaica
American Journal of the Medical Sciences
(2004) - et al.
IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus
American Journal of the Medical Sciences
(1999) Infection in systemic lupus erythematosus
Rheumatic Diseases Clinics of North America
(1998)- et al.
Tuberculosis among Filipino patients with systemic lupus erythematosus
Seminars in Arthritis and Rheumatism
(1996) - et al.
Long-term prognosis and causes of death in systemic lupus erythematosus
American Journal of Medicine
(2006) - et al.
Mortality studies in SLE: how far can we improve survival of patients with SLE
Autoimmunity Reviews
(2004)
Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden
Lupus
Estimating the incidence of systemic lupus erythematosus in a tropical region (Natal, Brazil)
Lupus
Differences in systemic lupus erythematosus among 4 racial groups in South Africa
Arthritis & Rheumatism
Prevalence of systemic lupus erythematosus in central Saudi Arabia
Saudi Medical Journal
Lupus in Hong Kong Chinese
Lupus
Prevalence of systemic lupus erythematosus and associated comorbidities in Puerto Rico
Journal of Clinical Rheumatology
Rheumatic disease in an Australian aboriginal community in North Queensland, Australia. A WHO-ILAR COPCORD survey
The Journal of Rheumatology
Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach
The Journal of Rheumatology
Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis, and gout in Shanghai, China: a COPCORD study
The Journal of Rheumatology
Systemic lupus erythematosus: the face of Asia
Annals of the New York Academy of Sciences
The epidemiology of systemic lupus erythematosus in populations of African ancestry: a critical review of the ‘prevalence gradient hypothesis’
Arthritis & Rheumatism
Systemic lupus erythematosus: genes versus environment in high risk populations
Lupus
Systemic lupus erythematosus-associated defects in the inhibitory receptor FcgammaRIIb reduce susceptibility to malaria
Proceedings of the National Academy of Sciences of the United States of America
Systemic lupus erythematosus in Trinidadian children
Annals of Tropical Paediatrics
Demographics and presenting clinical features of childhood systemic lupus erythematosus
South Africa Medical Journal
Childhood lupus nephritis: 12 years experience from North India
Rheumatology International
An overview of clinical manifestations and survival of systemic lupus erythematosus in Asia
APLAR Journal of Rheumatology
Causes and predictors of death in South Africans with systemic lupus erythematosus
Rheumatology (Oxford)
Lessons from the ‘Euro-Lupus Cohort’
Annales Medicine Interne (Paris)
The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradient
Arthritis & Rheumatism
Ethnic variation in disease patterns and health outcomes in systemic lupus erythematosus
The Journal of Rheumatology
Clinical and autoantibody correlations in Orientals with systemic lupus erythematosus
Annals of the Rheumatic Diseases
Clinical profile of Chinese patients with systemic lupus erythematosus
Lupus
The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among ‘Hispanics’
Medicine (Baltimore)
Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus
Lupus
Severity of systemic lupus erythematosus with diffuse proliferative glomerulonephritis and the ineffectiveness of standard pulse intravenous cyclophosphamide therapy in Jamaican patients
Lupus
Hypertension and Afro-descendant ethnicity: a bad interaction for lupus nephritis treated with cyclophosphamide?
Lupus
Systemic lupus erythematosus and lupus syndromes in Senegal. A retrospective study of 30 patients seen over 10 years
Revue du Rhumatisme (English Ed.)
Discoid lupus erythematosus in the Nigerians
British Journal of Dermatology
Photosensitivity and anti-Ro (SS-A) antibodies in black patients with systemic lupus erythematosus (SLE)
British Journal of Rheumatology
Diffuse nail dyschromia in black patients with systemic lupus erythematosus
The Journal of Rheumatology
Systemic lupus erythematosus in a patient with human immunodeficiency virus infection–challenges in diagnosis and management
Clinical Rheumatology
Skin is the most frequently damaged system in recent-onset systemic lupus erythematosus in a tropical region
Clinical Rheumatology
Systemic lupus erythematosus in Saudi patients
Clinical Rheumatology
Systemic lupus erythematosus in Tunisia: demographic and clinical analysis of 100 patients
Lupus
Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups
Arthritis & Rheumatism
Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus
The Journal of Rheumatology
Prevalence and clinical correlates of anti-phospholipid antibodies in South Africans with systemic lupus erythematosus
Scandinavian Journal of Rheumatology
Cited by (82)
Traditional Chinese formulas reduce hospitalization for infection among patients with systemic lupus erythematosus in Taiwan
2023, Journal of Herbal MedicineMusculoskeletal Disorders
2023, Manson's Tropical Diseases, Fourth EditionRenal Disease in the Tropics
2023, Manson's Tropical Diseases, Fourth EditionImproving musculoskeletal health for children and young people – A ‘call to action’
2020, Best Practice and Research: Clinical RheumatologyCitation Excerpt :Juvenile systemic lupus erythematosus (JSLE) is the most common connective disease in children and is life-threatening with no cure. Prevalence and incidence rates of JSLE (3.3–24 per 100,000 children and 0.3–0.9 per 100, 000 children per year, respectively) vary around the world [72] and JSLE is reported to be more common and more severe in Asia, SEA, Latin America and Africa [73–77] compared with the USA and Europe [72,78]. Such variation may be attributed to genetic background, ethnicity as well as ascertainment and selection bias.
Mortality of patients with systemic lupus erythematosus admitted to the intensive care unit – A retrospective single-center study
2018, Best Practice and Research: Clinical RheumatologyCitation Excerpt :Nevertheless, ICU mortality of patients with SLE remains high and ranges from 20% to 79% [6–8,16–22,24–26]. This significant variability in mortality rates among various study samples may be attributed to multiple factors including differences in baseline patient characteristics, differences in disease manifestations and severity, admission outcome, health care referral systems, availability of therapy, and several other factors [27]. The identification of prognostic variables associated with mortality in patients with SLE that are admitted to the ICU could help clinicians recognize high-risk SLE patients and assist in the development of better treatment modalities to care for these patients in the ICU setting.
The musculoskeletal system and bone metabolism
2018, Dubois' Lupus Erythematosus and Related Syndromes